La Louviere

• Baricitinib for treating hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase II … Not authorised
  2023-503480-42-00 10 Hospital-acquired pneumonia
• MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending
  2024-513889-19-00 5 Multiple Myeloma
• Multicentric study evaluating the usefulness of early PSMA PET scan in metastatic renal cancer requiring standard immunotherapy treatment. Pending
  2024-517098-26-00 4 metastatic clear cell Renal Carcinoma Cell
• A Phase III study evaluating the efficacy of atezoliumab administration in addition to BCG (Bacillus Calmette-Guerin) for 1 year in patient … Pending
  2024-517621-54-00 5 High-risk non-muscle invasive bladder cancer (NMIBC) after transurethr
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Pending
  2025-521587-35-00 5 Metastatic colorectal cancer
• Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiot … Pending
  2025-523575-36-00 4 Locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
• Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer Recruiting
  2025-522107-18-00 4 2026-05-19 Locally advanced or metastatic Non-Small Cell Lung Cancer
• A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) Recruiting
  2025-521792-31-01 5 2026-04-07 Homozygous Familial Hypercholesterolemia (HoFH)
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• A phase III study on using immunotherapy and radiotherapy to treat limited spread of Head and Neck Cancer Recruiting
  2023-504478-39-00 5 2025-05-23 Squamous cell carcinoma of head and neck
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial Recruiting
  2022-501551-90-00 10 2023-12-13 Prostate cancer
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn … Recruiting
  2022-501709-11-00 5 2023-06-06 Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
• (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Recruiting
  2022-501427-24-00 4 2023-04-25 Nonadvanced Systemic Mastocytosis
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting
  2022-501007-28-00 5 2023-04-18 Breast Neoplasms
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan … Recruiting
  2023-505749-14-00 5 2022-03-20 c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
• A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit … Recruiting
  2024-520101-39-00 5 2026-04-01 TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
• Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-522713-29-00 5 2026-03-12 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• Radiopharmaceutical treatment of advanced kidney cancer Recruiting
  2024-517899-38-00 4 2026-02-25 Clear Cell Renal Cell Carcinoma (ccRCC)

Showing 1–24 of 110 trials